ArticleAnnals of medicine and surgery (2012)2026
Nanorobotics in cancer care: innovation without translation?
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading global health burden, with approximately 19.3 million new cases reported worldwide. Limitations of conventional therapies have accelerated interest in nanobots as precision tools for cancer diagnosis and treatment. Their nanoscale dimensions allow targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficiency, including hyperthermia-based interventions. Advanced nanobot designs, such as isotope-labeled nanocarbon constructs, three-dimensional DNA nanobots, DNA-origami carriers, and magnetically propelled systems, demonstrate promising capabilities in biomarker detection, controlled drug release, and tumor-specific coagulation. However, despite these innovations, significant translational challenges persist, including safety concerns, off-target effects, and difficulties in external magnetic control. Bridging these gaps will require robust regulatory frameworks, improved nano-tumor biology insights, scalable manufacturing, and the integration of artificial intelligence-driven personalization. Addressing these issues will be pivotal for the clinical incorporation of nanobots in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.